Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment: An Open-Label, Flexible-Dosing, Multicentre Study

Author： Swift Steven E.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.29, Iss.5, 2009-01, pp. : 305-316

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Experience with Etanercept in the Treatment of Rheumatoid Arthritis in Elderly and Younger Patients: Patient-Reported Outcomes from Multiple Controlled and Open-Label Extension Studies

By Schiff Michael H.  

Drugs & Aging, Vol. 23, Iss. 2, 2006-01 ,pp. : 167-178

Adis International

Access to resources Recommend Favorite

Extended-release tolterodine is an effective and convenient option in the treatment of overactive bladder

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 2, 2005-02 ,pp. : 1-5

Adis International

Access to resources Recommend Favorite

Food Does Not Influence the Pharmacokinetics of a New Extended Release Formulation of Tolterodine for Once Daily Treatment of Patients with Overactive Bladder

By Olsson B.  

Clinical Pharmacokinetics, Vol. 40, Iss. 2, 2001-01 ,pp. : 135-143

Adis International

Access to resources Recommend Favorite

Oxycodone Controlled-Release as First-Choice Therapy for Moderate-to-Severe Cancer Pain in Italian Patients: Results of an Open-Label, Multicentre, Observational Study

By Silvestri Barbara  

Clinical Drug Investigation, Vol. 28, Iss. 7, 2008-01 ,pp. : 399-407

Adis International

Access to resources Recommend Favorite

Tolterodine for the treatment of overactive bladder

By Salvatore Stefano   Serati Maurizio   Bolis Pierfrancesco  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 7, 2008-05 ,pp. : 1249-1255

Informa Healthcare

Access to resources Recommend Favorite